Jennifer Evans Stacey
CIK: 0001321326
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Aug 14, 2026NEOG
NEOGEN CORP
Award(A)Direct38.6K shares at avg. $11.65$450K - Jun 24, 2026CNTX
Context Therapeutics Inc.
Award(A)DirectStock Option (right to buy)
45K shares- - May 1, 2026NEOG
NEOGEN CORP
Award(A)Direct39.3K shares at avg. $9.53$375K - Jun 12, 2025CNTX
Context Therapeutics Inc.
Award(A)DirectStock Option (right to buy)
123.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 14, 2026 |  NEOG NEOGEN CORP | Award(A) | 38,627 | $11.65 | $450,005 | Direct |
| Jun 24, 2026 |  CNTX Context Therapeutics Inc. | Award(A) Stock Option (right to buy) | 45,000 | - | - | Direct |
| May 1, 2026 | NEOG NEOGEN CORP | Award(A) | 39,349 | $9.53 | $374,996 | Direct |
| Jun 12, 2025 | CNTX Context Therapeutics Inc. | Award(A) Stock Option (right to buy) | 123,500 | - | - | Direct |
1-4 of 4 transactions
About Stacey Jennifer Evans
Stacey Jennifer Evans (SEC CIK 0001321326) files insider reports with the SEC as Chief Legal Officer of NEOGEN CORP (NEOG) and Director of Context Therapeutics Inc. (CNTX).
Signal8 holds 5 ownership filings by Stacey Jennifer Evans (1 Form 3, 4 Form 4), filed between Jun 12, 2025 and Aug 14, 2026. Those filings report 4 transactions, from Jun 12, 2025 to Aug 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Stacey Jennifer Evans's filings is in LANSING, MI.
Recent filings by Stacey Jennifer Evans
Other insiders filing for NEOGEN CORP (NEOG)
- Freels Joe B, Chief Commercial Officer
- Hastings Gregory S, VP, Animal Health
- Woteki Catherine E, Director
- RODRIGUEZ RAFAEL A, Director
- Burke Kevin M, Chief HR Officer
- Gupta Aashima, Director